Identification of Eight Key MiRNAs Associated with Renal Cell Carcinoma: A Meta-analysis

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Oct 23

PMID 30344735

Citations 13

Authors

Guanghui Ying

Ruilan Wu

Min Xia

Xiapei Fei

Qi En He

Chenqin Zha

Fuquan Wu

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma (RCC) is the most common renal carcinoma in the human kidney. To date, to the best of our knowledge, there are no biomarkers for the early monitoring and diagnosis of RCC patients. The present study aimed to develop deeper insight into the molecular mechanisms of microRNAs (miRNAs/miRs) in the regulation of RCC development and to reveal candidate miRNA biomarkers in human RCC. A meta-analysis was used to integrate the published and independent RCC miRNA expression profiling investigations that compared the miRNA expression profiles in RCC samples with control samples. The meta-signature miRNA target genes were then predicted in TargetScan. The predicted targets were further analyzed using Gene Ontology and pathway enrichment analysis with the Database for Annotation, Visualization and Integrated Discovery online tool, and then the transcription factors of meta-signature miRNA target genes were identified in Tfacts. A total of 7 publicly available and independent RCC miRNA expression profiling datasets were collected, and 2 upregulated (hsa-miR-155-5p and hsa-miR-210-5p) and 6 downregulated (hsa-miR-138-5p, hsa-miR-141-5p, hsa-miR-200c-5p, hsa-miR-362-5p, hsa-miR-363-5p and hsa-miR-429) meta-signature miRNAs in renal carcinoma were identified. The targeted gene enrichment analysis indicated that the meta-signature miRNAs may influence several pathways that participate in cancerogenesis, including the 'rap1 signaling pathway', 'renal cell carcinoma' and 'microRNAs in cancer'. Overall, the present meta-analysis identified 2 upregulated and 6 downregulated meta-signature miRNAs from 7 renal carcinoma datasets, the dysregulated miRNAs that may contribute to kidney carcinoma development. This research may reveal candidate miRNA biomarkers in human RCC.

Citing Articles

Exploring prognostic implications of miRNA signatures and telomere maintenance genes in kidney cancer.

Yerukala Sathipati S, Jeong S, Sharma P, Mayer J, Sharma R, Ho S Mol Ther Oncol. 2024; 32(4):200874.

PMID: 39399813 PMC: 11467672. DOI: 10.1016/j.omton.2024.200874.

ZEB family is a prognostic biomarker and correlates with anoikis and immune infiltration in kidney renal clear cell carcinoma.

Lin S, Chen Q, Tan C, Su M, Min L, Ling L BMC Med Genomics. 2024; 17(1):153.

PMID: 38840097 PMC: 11151722. DOI: 10.1186/s12920-024-01895-7.

The role of non-coding RNAs in chemotherapy for gastrointestinal cancers.

Dashti F, Mirazimi S, Rabiei N, Fathazam R, Rabiei N, Piroozmand H Mol Ther Nucleic Acids. 2021; 26:892-926.

PMID: 34760336 PMC: 8551789. DOI: 10.1016/j.omtn.2021.10.004.

MicroRNA-362-5p promotes the proliferation and inhibits apoptosis of trophoblast cells via targeting glutathione-disulfide reductase.

Zhang C, Zhao D Bioengineered. 2021; 12(1):2410-2419.

PMID: 34107852 PMC: 8806602. DOI: 10.1080/21655979.2021.1933678.

Identification of RCC Subtype-Specific microRNAs-Meta-Analysis of High-Throughput RCC Tumor microRNA Expression Data.

Kajdasz A, Majer W, Kluzek K, Sobkowiak J, Milecki T, Derebecka N Cancers (Basel). 2021; 13(3).

PMID: 33535553 PMC: 7867039. DOI: 10.3390/cancers13030548.

References

Ortholan C, Puissegur M, Ilie M, Barbry P, Mari B, Hofman P . MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets. Curr Med Chem. 2009; 16(9):1047-61. DOI: 10.2174/092986709787581833. View

Xu M, Chen X, Chen D, Yu B, Huang Z . FoxO1: a novel insight into its molecular mechanisms in the regulation of skeletal muscle differentiation and fiber type specification. Oncotarget. 2016; 8(6):10662-10674. PMC: 5354690. DOI: 10.18632/oncotarget.12891. View

Gao Y, Ma X, Yao Y, Li H, Fan Y, Zhang Y . miR-155 regulates the proliferation and invasion of clear cell renal cell carcinoma cells by targeting E2F2. Oncotarget. 2016; 7(15):20324-37. PMC: 4991458. DOI: 10.18632/oncotarget.7951. View

Song F, Yang D, Liu B, Guo Y, Zheng H, Li L . Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res. 2013; 20(4):878-89. DOI: 10.1158/1078-0432.CCR-13-1844. View

Kolde R, Laur S, Adler P, Vilo J . Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 2012; 28(4):573-80. PMC: 3278763. DOI: 10.1093/bioinformatics/btr709. View

Chen Z, Tang Z, He Y, Liu L, Li D, Chen X . miRNA-205 is a candidate tumor suppressor that targets ZEB2 in renal cell carcinoma. Oncol Res Treat. 2014; 37(11):658-64. DOI: 10.1159/000368792. View

Tweedie S, Ashburner M, Falls K, Leyland P, McQuilton P, Marygold S . FlyBase: enhancing Drosophila Gene Ontology annotations. Nucleic Acids Res. 2008; 37(Database issue):D555-9. PMC: 2686450. DOI: 10.1093/nar/gkn788. View

Li Y, Chen D, Li Y, Jin L, Liu J, Su Z . Oncogenic cAMP responsive element binding protein 1 is overexpressed upon loss of tumor suppressive miR-10b-5p and miR-363-3p in renal cancer. Oncol Rep. 2016; 35(4):1967-78. DOI: 10.3892/or.2016.4579. View

Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X . MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res. 2014; 21(2):83-91. DOI: 10.3727/096504013X13775486749218. View

10.

Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N . Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 2012; 3(1):44-57. PMC: 3292891. DOI: 10.18632/oncotarget.417. View

11.

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

12.

Hurteau G, Carlson J, Spivack S, Brock G . Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007; 67(17):7972-6. DOI: 10.1158/0008-5472.CAN-07-1058. View

13.

Osanto S, Qin Y, Buermans H, Berkers J, Lerut E, Goeman J . Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One. 2012; 7(6):e38298. PMC: 3380046. DOI: 10.1371/journal.pone.0038298. View

14.

Wu D, Niu X, Pan H, Zhou Y, Zhang Z, Qu P . Tumor-suppressing effects of microRNA-429 in human renal cell carcinoma via the downregulation of Sp1. Oncol Lett. 2016; 12(4):2906-2911. PMC: 5038608. DOI: 10.3892/ol.2016.4953. View

15.

Xiong F, Liu K, Zhang F, Sha K, Wang X, Guo X . MiR-204 inhibits the proliferation and invasion of renal cell carcinoma by inhibiting RAB22A expression. Oncol Rep. 2016; 35(5):3000-8. DOI: 10.3892/or.2016.4624. View

16.

Weng L, Wu X, Gao H, Mu B, Li X, Wang J . MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol. 2010; 222(1):41-51. DOI: 10.1002/path.2736. View

17.

Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R . Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012; 10:55. PMC: 3340316. DOI: 10.1186/1479-5876-10-55. View

18.

Huang X, Huang M, Kong L, Li Y . miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma. Cell Prolif. 2015; 48(5):593-9. PMC: 6496015. DOI: 10.1111/cpr.12207. View

19.

Wang C, Hu J, Lu M, Gu H, Zhou X, Chen X . A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Sci Rep. 2015; 5:7610. PMC: 5154588. DOI: 10.1038/srep07610. View

20.

Nakada C, Tsukamoto Y, Matsuura K, Nguyen T, Hijiya N, Uchida T . Overexpression of miR-210, a downstream target of HIF1α, causes centrosome amplification in renal carcinoma cells. J Pathol. 2011; 224(2):280-8. DOI: 10.1002/path.2860. View